BCL2 and cancer: In this context, Choi et al. [148] used anti-apoptotic Bcl-2 gene-targeting siRNA (Bcl-2 siRNA) and Ca2+-glued it onto bare MSNs, which were then co-loaded with the anti-cancer agent doxorubicin (DOX) to construct siRNA/DOX@Ca2+ MSNs.